GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (HKSE:03347) » Definitions » Piotroski F-Score

Hangzhou Tigermed Consulting Co (HKSE:03347) Piotroski F-Score : 5 (As of Apr. 01, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Hangzhou Tigermed Consulting Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hangzhou Tigermed Consulting Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Hangzhou Tigermed Consulting Co's Piotroski F-Score or its related term are showing as below:

HKSE:03347' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 6
Current: 5

During the past 13 years, the highest Piotroski F-Score of Hangzhou Tigermed Consulting Co was 6. The lowest was 3. And the median was 5.


Hangzhou Tigermed Consulting Co Piotroski F-Score Historical Data

The historical data trend for Hangzhou Tigermed Consulting Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Tigermed Consulting Co Piotroski F-Score Chart

Hangzhou Tigermed Consulting Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 4.00 3.00 3.00 5.00

Hangzhou Tigermed Consulting Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 2.00 4.00 5.00 5.00

Competitive Comparison of Hangzhou Tigermed Consulting Co's Piotroski F-Score

For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hangzhou Tigermed Consulting Co's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Hangzhou Tigermed Consulting Co's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was 255.359 + 277.508 + 352.973 + -435.914 = HK$450 Mil.
Cash Flow from Operations was 156.649 + 35.659 + 442.005 + 553.302 = HK$1,188 Mil.
Revenue was 1803.482 + 1828.014 + 1882.096 + 1639.416 = HK$7,153 Mil.
Gross Profit was 682.332 + 758.881 + 701.624 + 290.12 = HK$2,433 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was
(32464.169 + 32665.286 + 32745.348 + 33335.914 + 30611.243) / 5 = HK$32364.392 Mil.
Total Assets at the begining of this year (Dec23) was HK$32,464 Mil.
Long-Term Debt & Capital Lease Obligation was HK$772 Mil.
Total Current Assets was HK$6,726 Mil.
Total Current Liabilities was HK$3,910 Mil.
Net Income was 647.467 + 896.771 + 526.985 + 158.867 = HK$2,230 Mil.

Revenue was 2055.397 + 2085.051 + 2080.65 + 1896.134 = HK$8,117 Mil.
Gross Profit was 814.976 + 837.359 + 856.525 + 622.328 = HK$3,131 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(30649.923 + 32087.91 + 32448.833 + 32258.892 + 32464.169) / 5 = HK$31981.9454 Mil.
Total Assets at the begining of last year (Dec22) was HK$30,650 Mil.
Long-Term Debt & Capital Lease Obligation was HK$938 Mil.
Total Current Assets was HK$12,408 Mil.
Total Current Liabilities was HK$4,527 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hangzhou Tigermed Consulting Co's current Net Income (TTM) was 450. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hangzhou Tigermed Consulting Co's current Cash Flow from Operations (TTM) was 1,188. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=449.926/32464.169
=0.01385916

ROA (Last Year)=Net Income/Total Assets (Dec22)
=2230.09/30649.923
=0.07276005

Hangzhou Tigermed Consulting Co's return on assets of this year was 0.01385916. Hangzhou Tigermed Consulting Co's return on assets of last year was 0.07276005. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Hangzhou Tigermed Consulting Co's current Net Income (TTM) was 450. Hangzhou Tigermed Consulting Co's current Cash Flow from Operations (TTM) was 1,188. ==> 1,188 > 450 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=771.891/32364.392
=0.02385001

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=937.732/31981.9454
=0.02932067

Hangzhou Tigermed Consulting Co's gearing of this year was 0.02385001. Hangzhou Tigermed Consulting Co's gearing of last year was 0.02932067. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=6725.998/3909.657
=1.72035501

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=12407.982/4526.862
=2.74096758

Hangzhou Tigermed Consulting Co's current ratio of this year was 1.72035501. Hangzhou Tigermed Consulting Co's current ratio of last year was 2.74096758. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Hangzhou Tigermed Consulting Co's number of shares in issue this year was 851.98. Hangzhou Tigermed Consulting Co's number of shares in issue last year was 862.751. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2432.957/7153.008
=0.34013061

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=3131.188/8117.232
=0.38574578

Hangzhou Tigermed Consulting Co's gross margin of this year was 0.34013061. Hangzhou Tigermed Consulting Co's gross margin of last year was 0.38574578. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=7153.008/32464.169
=0.22033547

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=8117.232/30649.923
=0.26483695

Hangzhou Tigermed Consulting Co's asset turnover of this year was 0.22033547. Hangzhou Tigermed Consulting Co's asset turnover of last year was 0.26483695. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hangzhou Tigermed Consulting Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Hangzhou Tigermed Consulting Co  (HKSE:03347) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Hangzhou Tigermed Consulting Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Hangzhou Tigermed Consulting Co Business Description

Traded in Other Exchanges
Address
Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.
Executives
Sands Capital Management, Llc 2101 Beneficial owner
Sands Capital Management, Lp 2201 Interest of corporation controlled by you
Sands Family Trust, Llc 2201 Interest of corporation controlled by you
Sands Frank Melville Jr. 2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
F-j Sands Family I, Llc 2201 Interest of corporation controlled by you
2017 Eagle Holdings Llc 2201 Interest of corporation controlled by you
Citigroup Inc. 2201 Interest of corporation controlled by you
Ubs Group Ag 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co. 2502 Approved lending agent
Ninety One Plc/ Ninety One Ltd 2102 Investment manager
Ninety One Uk Limited 2102 Investment manager
Baillie Gifford & Co 2102 Investment manager

Hangzhou Tigermed Consulting Co Headlines

No Headlines